9926:HKG
Akeso Inc
HK$91,30
arrow_upward
+0,94%(+0,85) 1D
16 Okt., 16:08:14 GMT+8 · HKD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 9926...
Open
HK$92,15
High
HK$95,30
Low
HK$90,15
Mkt. cap
84,10 mjd
Avg. vol.
10,45 m
Volume
11,09 m
52-wk high
HK$156,00
52-wk low
HK$80,20
EPS
-HK$1,24
No. of employees
4 k
Open
HK$92,15
High
HK$95,30
Low
HK$90,15
Mkt. cap
84,10 mjd
Avg. vol.
10,45 m
Volume
11,09 m
52-wk high
HK$156,00
52-wk low
HK$80,20
EPS
-HK$1,24
No. of employees
4 k
News stories
From web sources and news partners
Simply Wall Street
·
1 uur gelede
Is Akeso (SEHK:9926) Undervalued On Its Phase III Colon Cancer Trial News?
Yahoo Finance
·
1 dag gelede
Will Phase III Colon Cancer Trial Change Akeso Stock Narrative
Profile
Akeso, Inc is a publicly listed Chinese biopharmaceutical company that is headquartered in Zhongshan, Guangdong.
It is best known for developing Ivonescimab, a cancer treatment antibody. Wikipedia
About Akeso Inc
CEOMichelle Xia | Michelle Xia
Employees4,08 k
Founded19 Mrt. 2012
Headquarters-
Sector-
Websiteakesobio.com